Bone marrow transplant (BMT), also known as hematopoietic stem cell transplant, is regarded as a lifesaving and even curative therapy. It is important to note that no surgery is required; rather, stem cells are transfused from a bag, like a blood transfusion. BMT has revolutionized the treatment of several severe pediatric disorders, including thalassemia major, severe aplastic anemia, immunodeficiency disorders, high-risk blood cancers, and certain neurological and metabolic disorders such as metachromatic leukodystrophy and mucopolysaccharidoses (MPS). Despite major progress in transplant science, many still see BMT as a last resort. This can have a high effect on the survival rate, recovery process, and overall quality of life.Why Are Bone Marrow Transplants Delayed?One big reason for postponing transplant decisions is the belief that BMT should only be considered after all standard therapies have failed. There is also limited awareness about the excellent outcomes and curative potential of BMT in many benign pediatric disorders when performed early. Children often go through repeated chemotherapy cycles, frequent blood transfusions, or long-term supportive care before anyone seriously discusses transplant. While this therapy may help in stabilizing the condition temporarily, it can cause lasting damage to the organs, increase the risk of infections, and affect the immune system, making transplant surgeries risky and less successful.Delays Can Reduce Success Of TransplantFor instance, in children with thalassemia major, years of blood transfusions can lead to iron overload, which harms the heart and liver, reducing their ability to handle intense transplant conditioning. Likewise, in diseases like MPS, metachromatic leukodystrophy, where the disease has progressed, role of BMT becomes guarded.Why Early Referral And Timely Treatment MattersIn addition to medical hesitation, systemic and emotional barriers also cause delays. The long-standing belief that a fully matched donor is essential has also changed significantly, with recent years witnessing remarkable growth and success in haploidentical (half-matched) donor BMTs. There are challenges related to awareness and affordability in India. The fear of risks such as graft-versus-host disease, infection, or death from transplant surgery results in parents adopting a "wait and see" attitude until their child’s health deteriorates further.It is ironic that lack of awareness and accessibility to pediatric bone marrow transplant specialists are also among the factors that can cause delay in proper diagnosis and referral. Yet, the wait could put the children’s lives at greater risk due to the damage caused by chemotherapy and other forms of treatment.Modern medical professionals emphasize that BMT does not have to be used only as a “last resort” treatment but can be administered in a timely manner to provide a cure for the patient.